Nicht durch eine zystische Fibrose bedingte (Non-CF-) Bronchiektasen

Schlüsselwörter

Bronchiektasen - Antibiotika - hypertone Kochsalzlösung - Mannitol - mukoziliäre Clearance - Physiotherapie

Keywords

bronchiectasis - antibiotics - hypertonic saline solution - mannitol - mucociliary clearance - physical therapy

• Literatur

• 1 Altenburg J, de Graaff CS, Stienstra Y et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309: 1251-1259
• 2 Andres J, Hellmann A, Horst M. Versorgungsbericht 2010 – ambulante Pneumologie. Heidenheim: Bundesverband der Pneumologen (BdP) in Kooperation mit dem Wissenschaftlichen Informationsnetzwerk der niedergelassenen Pneumologen (WINPNEU); 2011
• 3 Bilton D, Daviskas E, Anderson SD et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013; 144: 215-225
• 4 Bilton D, Tino G, Barker A et al. Inhaled mannitol for non-cystic fibrosis broncheictasis: Results of a 12 month, multi-centre, double-blind, controlled study. Eur Respir J 2013; 42 (Suppl. 57) 386s
• 5 De Soyza A, Brown JS, Loebinger MR. Research priorities in bronchiectasis. Thorax 2013; 68: 695-696
• 6 Figueiredo BC de, Ibiapina CdaC. The role of macrolides in noncystic fibrosis bronchiectasis. Pulm Med 2011; 2011: 751982
• 7 Flick H. Österreichische Gesellschaft für Pneumologie. Inhalative Antibiotika zur Therapie von Pseudomonasinfektionen bei Non-CF Bronchiektasien – Update 2013. http://www.ogp.at/aktuelles/Inhalative_Antibiotika.pdf (letzter Zugriff 10.2.2014)
• 8 Haworth C, Bilton D, Kenyon R. Nebulised colistimethate sodium improves quality of life in patients with bronchiectasis colonised by pseudomonas aeruginosa. Eur Respir J 2013; 42 (Suppl. 57) 577-578s
• 9 Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011; 105: 1831-1835
• 10 Li AM, Sonnappa S, Lex C et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management?. Eur Respir J 2005; 26: 8-14
• 11 Mandal P, Sidhu MK, Kope L et al. A pilot study of pulmonary rehabilitation and chest physiotherapy versus chest physiotherapy alone in bronchiectasis. Respir Med 2012; 106: 1647-1654
• 12 Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 823-831
• 13 Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011; 140: 1130-1137
• 14 Murray MP, Govan JR, Doherty CJ et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499
• 15 Nicolson CH, Stirling RG, Borg BM et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 661-667
• 16 O'Donnell AE, Barker AF, Ilowite JS et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113: 1329-1334
• 17 Rademacher J, Ringshausen FC. Non-CF-Bronchiektasen mit Fokus auf die allergische bronchopulmonale Aspergillose. Pneumologie 2013; 67: 40-47; quiz 48-49
• 18 Rademacher J, Ringshausen FC. Prevention and treatment of exacerbations of non-cystic fibrosis bronchiectasis. Eur Respir Monogr 2013; 60: 127-136
• 19 Ringshausen FC, Apel RM, Bange FC et al. Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005-2011. BMC Infect Dis 2013; 13: 231
• 20 Ringshausen FC, de Roux A, Pletz MW et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One 2013; 8: e71109
• 21 Ringshausen FC, Pletz MW, de Roux A et al. Ätiologie und Mikrobiologie von Non-CF-Bronchiektasen: Erfahrungen eines einzelnen Zentrums. Pneumologie 2012; 66: P10
• 22 Schembri S, Williamson PA, Short PM et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013; 346: f1235
• 23 Seitz AE, Olivier KN, Adjemian J et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000-2007. Chest 2012; 142: 432-439
• 24 Seitz AE, Olivier KN, Steiner CA et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010; 138: 944-949
• 25 Serisier DJ, Bilton D, De Soyza A et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013; 68: 812-817
• 26 Serisier DJ, Martin ML, McGuckin MA et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309: 1260-1267
• 27 Wilson R, Welte T, Polverino E et al. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2012; 41: 1107-1115
• 28 Wong C, Jayaram L, Karalus N et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667